SynthesisPloS one2014
Effects of anabolic steroids on chronic obstructive pulmonary disease: a meta-analysis of randomised controlled trials.
Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Anabolic-androgenic steroids for patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis.Frontiers in medicine · 2022Pooled it
- Trial
- A pragmatic randomised controlled trial of preferred intensity exercise in depressed adult women in the United Kingdom: secondary analysis of individual variability of depression.BMC public health · 2019Trial
- Efficacy of interventions to alter measures of fat-free mass in people with COPD: a systematic review and meta-analysis.ERJ open research · 2023Review
- Circulating testosterone levels and health outcomes in chronic obstructive pulmonary disease: results from ECLIPSE and ERICA.BMJ open respiratory research · 2023Observational
- Article
- Role of nutrition in patients with coexisting chronic obstructive pulmonary disease and sarcopenia.Frontiers in nutrition · 2023Review
- Long-Term Outcome of Chronic Obstructive Pulmonary Disease: A Review.Tuberculosis and respiratory diseases · 2022Review
- Case Report: Resolution of radiation pneumonitis with androgens and growth hormone.Frontiers in oncology · 2022Article
- Influenza A Virus-Driven Airway Inflammation may be Dissociated From Limb Muscle Atrophy in Cigarette Smoke-Exposed Mice.Frontiers in pharmacology · 2022Article
- Towards Personalized Management of Sarcopenia in COPD.International journal of chronic obstructive pulmonary disease · 2021Review
- Treatment of severe stable COPD: the multidimensional approach of treatable traits.ERJ open research · 2020Review
- Novel insights in ICU-acquired respiratory muscle dysfunction: implications for clinical care.Critical care (London, England) · 2017Review
- Cachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspective.Journal of cachexia, sarcopenia and muscle · 2016Review
- Defining COPD-Related Comorbidities, 2004-2014.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2014Review
- Testosterone replacement therapy and hospitalization rates in men with COPD.Chronic respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnabolic steroids are known to improve body composition and muscle strength in healthy people. However, whether anabolic steroids improve the physical condition and function in patients with chronic obstructive pulmonary disease (COPD) remains undetermined. A meta-analysis was conducted to review the current evidence regarding the effects of anabolic steroids on COPD patients.
methodsA comprehensive literature search of PubMed and EMBASE was performed to identify randomised controlled trials that examine the effects of anabolic steroids on COPD patients. Weighted mean differences (WMDs) with 95% confidence intervals were calculated to determine differences between anabolic steroid administration and control conditions.
resultsEight eligible studies involving 273 COPD patients were identified in this meta-analysis. Significant improvements were found in body weight (0.956 kg), fat-free mass (1.606 kg), St. George's Respiratory Questionnaire total score (-6.336) and symptom score (-12.148). The apparent improvements in maximal inspiratory pressure (2.740 cmH2O) and maximal expiratory pressure (12.679 cmH2O) were not significant. The effects on handgrip strength, forced expiratory volume in one second (FEV1), predicted FEV1 percent, PaO2, PaCO2 and six-min walk distance were negative, with WMDs of -0.245 kg, -0.096 L/sec, -1.996% of predicted, -1.648 cmHg, -0.039 cmHg and -16.102 meters, respectively.
conclusionsLimited evidence available from the published literature suggests that the benefit of anabolic steroids on COPD patients cannot be denied. However, further studies are needed to identify the specific benefits and adverse effects of anabolic steroids on COPD patients and to determine the optimal populations and regimes of anabolic steroids in COPD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.